A share price of Nektar Therapeutics [NKTR] is currently trading at $44.0, down -3.15%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NKTR shares have lost -13.93% over the last week, with a monthly amount drifted -25.64%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nektar Therapeutics [NASDAQ: NKTR] stock has seen the most recent analyst activity on November 26, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $102. Previously, H.C. Wainwright reaffirmed its Buy rating on June 24, 2025, and elevated its price target to $120. On June 24, 2025, BTIG Research reiterated its Buy rating and revised its price target to $100 on the stock. Jefferies upgraded its rating to a Buy but stick to its price target of $2 on April 11, 2025. Oppenheimer upgraded its rating to a Outperform but $6 remained the price target by the analyst firm on March 14, 2025. B. Riley Securities started tracking with a Buy rating for this stock on January 08, 2025, and assigned it a price target of $4. In a note dated December 10, 2024, H.C. Wainwright initiated an Buy rating and provided a target price of $6.50 on this stock.
Nektar Therapeutics experienced fluctuations in its stock price throughout the past year between $0.43 and $66.92. Currently, Wall Street analysts expect the stock to reach $123.67 within the next 12 months. Nektar Therapeutics [NASDAQ: NKTR] shares were valued at $44.0 at the most recent close of the market. An investor can expect a potential return of 181.07% based on the average NKTR price forecast.
Analyzing the NKTR fundamentals
Trailing Twelve Months sales for Nektar Therapeutics [NASDAQ:NKTR] were 62.60M which represents -51.13% decline. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at -1.57%, Pretax Profit Margin comes in at -1.82%, and Net Profit Margin reading is -1.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is -3.57 and Total Capital is -0.42. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 42.12 points at the first support level, and at 40.24 for the second support level. However, for the 1st resistance point, the stock is sitting at 46.38, and for the 2nd resistance point, it is at 48.77.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Nektar Therapeutics [NASDAQ:NKTR] is 4.24. Also, the Quick Ratio is 4.24, while the Cash Ratio stands at 0.62. Considering the valuation of this stock, the price to sales ratio is 14.30, the price to book ratio is 10.16.
Transactions by insiders
Recent insider trading involved Zalevsky Jonathan, Chief R&D Officer, that happened on Nov 25 ’25 when 1157.0 shares were sold. Chief Legal Officer, Wilson Mark Andrew completed a deal on Nov 25 ’25 to sell 630.0 shares. Meanwhile, President & CEO ROBIN HOWARD W sold 2207.0 shares on Nov 25 ’25.
